European Heart Journal Advance Access first published online on March 21, 2005
This version published online on April 4, 2005
European Heart Journal, doi:10.1093/eurheartj/ehi231
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Point Medical, Rond Point de la Nation, Dijon F-21 000, France
* To whom correspondence should be addressed. Aims To examine the efficacy and safety of coadministered ezetimibe (EZE) with fenofibrate (FENO) in patients with mixed hyperlipidaemia. Methods and results This was a multicentre, randomized, double-blind, placebo-controlled, parallel arm trial in patients with mixed hyperlipidaemia [LDL-cholesterol (LDL-C), 3.4-5.7 mmol/L (2.6-4.7 mmol/L for patients with type 2 diabetes); triglycerides (TG), 2.3-5.7 mmol/L] and no history of coronary heart disease (CHD), CHD-equivalent disease (except for type 2 diabetes), or CHD risk score >20%. A total of 625 patients was randomized in a 1 : 3 : 3 : 3 ratio to one of four daily treatments for 12 weeks: placebo; EZE 10 mg; FENO 160 mg; FENO 160 mg plus EZE 10 mg (FENO + EZE). The primary endpoint compared the LDL-C lowering efficacy of FENO + EZE vs. FENO alone. LDL-C, non-HDL-cholesterol (non-HDL-C), and apolipoprotein B were significantly (P < 0.001) reduced with FENO + EZE when compared with FENO or EZE alone. TG levels were significantly decreased and HDL-C was significantly increased with FENO + EZE and FENO treatments when compared with placebo (P < 0.001). Coadministration therapy reduced LDL-C by 20.4%, non-HDL-C by 30.4%, TG by 44.0%, and increased HDL-C by 19.0%. At baseline, >70% of all patients exhibited the small, dense LDL pattern B profile. A greater proportion of patients on FENO + EZE and FENO alone treatments shifted from a more atherogenic LDL size pattern to a larger, more buoyant, and less atherogenic LDL size pattern at study endpoint than those on placebo or EZE. All three active therapies were well tolerated. Conclusion Coadministration of EZE with FENO provided a complementary efficacy therapy that improves the atherogenic lipid profile of patients with mixed hyperlipidaemia.
Received October 26, 2004
Revised February 9, 2005
Accepted February 17, 2005
Clinical research
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia
2 Massachusetts General Hospital, Boston, MA, USA
3 Merck Research Laboratory, Rahway, NJ, USA
Michel Farnier, E-mail: mfarnier{at}ipac.fr
Abstract
The originally published version of this paper was incorrect. The list of names in the Appendix contained errors. The author apologizes that these were not identified earlier.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Miller Dyslipidemia and cardiovascular risk: the importance of early prevention QJM, September 1, 2009; 102(9): 657 - 667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Farnier, I. Perevozskaya, W. V. Taggart, D. Kush, and Y. B. Mitchel VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate J. Lipid Res., December 1, 2008; 49(12): 2641 - 2647. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dandona Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein Mayo Clin. Proc., March 1, 2008; 83(3): 333 - 342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zambon, P. Gervois, P. Pauletto, J.-C. Fruchart, and B. Staels Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators: Clinical and Experimental Evidence Arterioscler Thromb Vasc Biol, May 1, 2006; 26(5): 977 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D Meyers, Y. S. Moon, H. Ghanem, and N. D Wong Type Of Preexisting Lipid Therapy Predicts LDL-C Response to Ezetimibe Ann. Pharmacother., May 1, 2006; 40(5): 818 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. McKenney, M. Farnier, K.-W. Lo, H. E. Bays, I. Perevozkaya, G. Carlson, M. J. Davies, Y. B. Mitchel, and B. Gumbiner Safety and Efficacy of Long-Term Co-Administration of Fenofibrate and Ezetimibe in Patients With Mixed Hyperlipidemia J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1584 - 1587. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Tovar and D. B. Schering Management of Dyslipidemia in Special Populations Journal of Pharmacy Practice, April 1, 2006; 19(2): 63 - 78. [Abstract] [PDF]
|
|
|
|
|
|
M. Rizzo and K. Berneis Low-density lipoprotein size and cardiovascular risk assessment QJM, January 1, 2006; 99(1): 1 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Borja Ezetimibe coadministered with fenofibrate: some safety questions Eur. Heart J., November 1, 2005; 26(21): 2344 - 2344. [Full Text] [PDF]
|
|
|
|
|
|
M. Farnier, M. J. Davies, Y. B. Mitchel, and B. Gumbiner Ezetimibe coadministered with fenofibrate: some safety questions: reply Eur. Heart J., November 1, 2005; 26(21): 2344 - 2345. [Full Text] [PDF]
|
|
|
|
|
|
A. F.H. Stalenhoef Management of mixed hyperlipidaemia Eur. Heart J., May 1, 2005; 26(9): 856 - 857. [Full Text] [PDF]
|
|